A Phase 2/3 interventional study of riboflavin 0.1% and Riboflavin 0.1% in Keratoconus and Ectasia Corneal, sponsored by Price Vision Group. Completed at 1 site in United States. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2026-09-17.
Sponsored by Price Vision Group · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing riboflavin in Keratoconus — 5 open to participants now, 8 under way, 7 of them phase 3. Riboflavin · Keratoconus.
Among the 23 studies testing riboflavin in Keratoconus, this one is the 4th largest by enrollment, is the only one that started in 2019, is one of 4 in phase 2/3, and was the 18th registered.
313 studies on the registry are indexed under Keratoconus; 56 are open to participants now.
Browse Keratoconus studies →5 of the 23 studies testing riboflavin in Keratoconus are open now, in 1 country. Recruiting first, the newest first:
Price Vision Group · Sites in United States
Ages 10–90
Cornea and Laser Eye Institute · Sites in United States
Ages 18+ · Healthy volunteers
Cornea and Laser Eye Institute · Sites in United States
Ages 12+ · Healthy volunteers
Cornea and Laser Eye Institute · Sites in United States
Ages 12+ · Healthy volunteers
Kent Wellish MD
Ages 12+
By country, each count listing its studies:
Riboflavin: first FDA approval 1953 (M.V.I.-12 ADULT). What it is approved for, and how studies give it, is on its page →
Of the 37 Keratoconus studies recruiting now, 21 (57%) set no upper age limit and 11 (30%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.
This study: 10 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 16 · Phase 4 1
First in 2008; this study’s year is marked. 1 started in 2019.
This study's enrollment of 508 is above the median of 40 across 205 interventional studies indexed under Keratoconus.
Median enrollment 170 across the 23 interventional studies. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 23 have an industry lead sponsor. The 10 most frequent:
Price Vision Group is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Price Vision Group has 3 studies filed under Keratoconus — fewer than ten, so there is no comparison to draw.
1 of the studies testing riboflavin in Keratoconus that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04731727Kent Wellish MDTreating Corneal Thinning Conditions With CCL Vario Riboflavin (CXL) | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing riboflavin in Keratoconus, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study objective is to compare accelerated and standard corneal crosslinking for treatment of progressive keratoconus or corneal ectasia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Treatment with 0.1% riboflavin eye drops and 9 mW/cm2 UVA light for 10 minutes
Combination Product: riboflavin 0.1%
Treatment with 0.1% riboflavin eye drops and 3 mW/cm2 UVA light for 30 minutes
Combination Product: Riboflavin 0.1%
Use of riboflavin 0.1% eye drops and 9 mW/cm2 UVA light for 10 minutes
Use of riboflavin 0.1% eye drops and 3 mW/cm2 UVA light for 30 minutes
Change in maximum keratometry
assessed by corneal tomography
Time frame: 6 months
Change in corrected distance visual acuity
assessed with Snellen chart
Time frame: 6 months
Change in uncorrected distance visual acuity
assessed with Snellen chart
Time frame: 6 months
Plan to share: No
Ran from Apr 2019 to primary completion in Jun 2026, 86 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Riboflavin
Price Vision Group